$IPSC

Russotti Gregory sold $1K of IPSC

Russotti Gregory (See Remarks) sold 524 shares of Century Therapeutics, Inc. (IPSC) at $2.11 on 2026-06-08.

Original reporting
SEC EDGAR · Russotti Gregory
Published Jun 9, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IPSC
Bearish
medium confidence
Mentioned
$IPSC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IPSCBearishLow
01

Why it matters

Because it is a small, routine insider sale and not tied to a new corporate event, it is unlikely to drive fundamental repricing.

02

Market read

Traders may note marginal sentiment impact, but the disclosure is not a new fundamental catalyst.

03

What to watch

The article does not state a 10b5-1 plan and provides only a small sale size, limiting inference about future insider behavior.

Relevance 3/10Novelty 2/10Timing: filed 2026-06-09 (covers sale dated 2026-06-08)

Background

The article is an SEC EDGAR Form 4 disclosure of an officer’s open-market sale in Century Therapeutics, Inc.

Company-level read

Ticker impact

$IPSCBearishMedium confidence
Context

Century Therapeutics (IPSC) disclosed an officer open-market sale of 524 shares at $2.1110 on 2026-06-08 via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with ~$1.1K proceeds and no 10b5-1 plan stated; such prints are typically not material to valuation.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be non-informational (taxes, diversification) and may not reflect a change in outlook.

Key entities

  • Century Therapeutics, Inc.

    Company whose officer disclosed an open-market sale of shares via SEC Form 4.

  • Russotti Gregory

    Officer who sold 524 shares on 2026-06-08.

Related articles

$AZNMed

Biotech and Pharma Industry News | BioPharma Dive

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

$IPSCMedAI 8/10

New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa